- Agaric acid
-
- $98.00
-
2026-06-11
- CAS:666-99-9
- Purity: 98.99%
- Supply Ability: 10g
- Agaric acid
-
- $98.00
-
2026-06-11
- CAS:666-99-9
- Purity: 98.99%
- Supply Ability: 10g
- AGARIC ACID
-
- $9.80
-
2020-01-10
- CAS:666-99-9
- Min. Order: 1g
- Purity: ≥99%
- Supply Ability: 100kg
|
| | AGARIC ACID Basic information |
| Product Name: | AGARIC ACID | | Synonyms: | 3-nonadecanetricarboxylicacid,2-hydroxy-2;agaric;alpha-cetylcitricacid;laricicacid;n-hexadecylcitricacid;2-HYDROXY-1,2,3-NONADECANETRICARBOXYLIC ACID;AGARIC ACID;AGARICIN | | CAS: | 666-99-9 | | MF: | C22H40O7 | | MW: | 416.55 | | EINECS: | 211-566-5 | | Product Categories: | | | Mol File: | 666-99-9.mol |  |
| | AGARIC ACID Chemical Properties |
| Melting point | 142° (dec) | | alpha | D19 -9° (NaOH) | | Boiling point | 454.85°C (rough estimate) | | density | 1.0867 (rough estimate) | | refractive index | 1.5300 (estimate) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | Aqueous Base (Slightly), DMSO (Slightly) | | form | Solid | | pka | 2.93±0.36(Predicted) | | color | Pale Beige | | Merck | 13,186 | | InChI | 1S/C22H40O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20(25)26)22(29,21(27)28)17-19(23)24/h18,29H,2-17H2,1H3,(H,23,24)(H,25,26)(H,27,28) | | InChIKey | HZLCGUXUOFWCCN-UHFFFAOYSA-N | | SMILES | CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(CC(O)=O)C(O)=O || CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(CC(O)=O)C(O)=O |
| WGK Germany | 3 | | RTECS | RA5365000 | | Storage Class | 11 - Combustible Solids |
| | AGARIC ACID Usage And Synthesis |
| Uses | Agaric Acid has been used as antiperspirant. | | Uses | Agaric acid (Agaricic acid), an inducer of mitochondrial permeability transition (MPT), is used to study the MPT process at the level of the ADP and ATP exchange via the adenine nucleotide carrier/translocase. | | in vivo | Agaric acid (1-4% of the diet; 3 weeks) inhibits lipogenesis in rats[3]. | Animal Model: | Female Sprague-Dawley rats weighing 170-185 g[3] | | Dosage: | 1% and 4% of the diet | | Administration: | 3 weeks | | Result: | Significantly affected weight gain and food intake.
Decreased fatty acid synthesis and increased unsaponifiable lipid formation in the liver.
Caused a significant decrease in fatty acid synthesis and unsaponifiable lipid synthesis in adipose tissue at a dose of 4%.
|
| | Purification Methods | Crystallise the acid from EtOH. The trihydrazide has m 170o(dec) (from EtOH). [Brand.nge et al. Acta Chem Scand B 31 307 1977, Beilstein 3 I 186, 3 II 372, 3 III 1109, 3 IV 1284.] |
| | AGARIC ACID Preparation Products And Raw materials |
|